As CMS pursues a National Coverage Determination for monoclonal antibodies targeting amyloid beta plaque, such as Aduhelm, this could result in a boon for brain scans – such as Amyvid, an amyloid PET imaging scan – that evaluate amyloid beta neuritic plaque density.
Aduhelm Could Breathe New Life Into Alzheimer’s Diagnostics Such As Amyvid
